Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

Novo Nordisk filed the application after it announced on June 26, 2024 that it was stopping CLARION-CKD trial for Ocedurenone, a drug for uncontrolled hypertension and advanced chronic kidney disease ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

Novo Nordisk's blockbuster medication has gained another label expansion, now authorized for treating chronic kidney disease. New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's ...

Those who live with type 2 diabetes have an increased risk of developing chronic kidney disease and are ... Head of U.S. Diabetes Therapeutic Area at Novo Nordisk. "By spotlighting the real ...